These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

891 related items for PubMed ID: 22480748

  • 1. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [Abstract] [Full Text] [Related]

  • 2. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 4. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L.
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [Abstract] [Full Text] [Related]

  • 5. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G, Strehblow C, Fasching P.
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
    Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA.
    Arthritis Res Ther; 2014 Jun 17; 16(3):R125. PubMed ID: 24938855
    [Abstract] [Full Text] [Related]

  • 14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 17; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 15. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L, Thavaneswaran A, Chandran V, Gladman DD.
    Ann Rheum Dis; 2014 Jun 17; 73(6):1007-11. PubMed ID: 23619157
    [Abstract] [Full Text] [Related]

  • 16. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May 17; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 17. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
    Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F, Rapsomaniki P, Barton A, Boumpas DT, Sidiropoulos P, Goulielmos GN.
    PLoS One; 2013 May 17; 8(9):e74375. PubMed ID: 24040234
    [Abstract] [Full Text] [Related]

  • 18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov 17; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.